Epigenomics AG / Key word(s): Preliminary Results 26.02.2014 / 08:30 Revenue improved by 53% to EUR 1.6 million (2012: EUR 1.0 million) Net loss reduced by 39% to EUR 7.4 million (2012: EUR 12.2 million) through cost reductions; cash consumption of EUR 6.5 million reduced by 40% (2012: EUR 10.9 million) Decisive steps forward in […]
Author: mark
26. February 2014
Epigenomics AG: Epigenomics AG Reports Preliminary Results and Highlights for the Year Ended December 31, 2013
Read more
10. February 2014
Epigenomics AG: Epigenomics Further Strengthens Intellectual Property Coverage for Epi proColon in the U.S. and in China
Epigenomics AG / Key word(s): Patent 10.02.2014 / 11:30 Patents cover detection of colorectal cancer with Septin9 biomarker Berlin (Germany) and Germantown, MD (U.S.A.), February 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was granted key Intellectual Property (IP) rights related […]
06. February 2014
Epigenomics AG: Epigenomics announces Date for the FDA Advisory Committee Meeting to Review Epi proColon and for the Publication of Preliminary Financial Results 2013
Epigenomics AG / Key word(s): Miscellaneous 06.02.2014 / 14:00 Berlin (Germany) and Germantown, MD (U.S.A.), February 06, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that the date for the FDA Advisory Committee meeting for Epigenomics’ blood-based colorectal cancer screening test Epi proColon(R) was published […]
10. January 2014
Epigenomics AG: Epigenomics Begins Trading on OTCQX Marketplace in the U.S.
Epigenomics AG / Key word(s): Miscellaneous 10.01.2014 / 10:00 Press release Epigenomics Begins Trading on OTCQX Marketplace in the U.S. – BNY Mellon to act as Principal American Liaison (PAL) for Epigenomics on OTCQX – Epigenomics’ ADRs to start trading under ticker symbol EPGNY today Berlin, Germany, and Germantown, MD, U.S.A., January 10, 2014 – […]
09. January 2014
Epigenomics AG: Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
Epigenomics AG / Key word(s): Agreement 09.01.2014 / 08:30 Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China, January 9, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both […]
12. December 2013
Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
Epigenomics AG / Key word(s): Miscellaneous 12.12.2013 / 08:45 Berlin, Germany, and U.S.A., December 12, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the […]